Glucocorticoids Toxicity, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vasculitis
Conditions
Keywords
glucocorticoid toxicity index, Drug-Related Problem, Glucocorticoid, Rheumatoid Arthritis, Vasculitis, Clinical Pharmacist
Brief summary
Hypothesis 1: A reduction in side effects is achieved with monitoring glucocorticoid treatment by using the Glucocorticoid Toxicity Index (GTI) in patients using glucocorticoids. Hypothesis 2: Monitoring treatment by using GTI in patients using glucocorticoids causes a decrease in glucocorticoid toxicity and an increase in the quality of life of patients. Hypothesis 3: With the involvement of the clinical pharmacist in the multidisciplinary team in patients using glucocorticoids, the drug-related problems of the patients are detected and prevented. The aim of this study was to evaluate the glucocorticoid treatment of patients with RA, SLE and vasculitis treated with glucocorticoids prospectively by a multidisciplinary team with GTI. In addition, it was aimed to identify and prevent drug-related problems by reviewing all drugs used in these patients by the clinical pharmacist.
Detailed description
In this study, the side effects of glucocorticoids used by patients will be evaluated using the Glucocorticoid Toxicity Index (GTI) index. This index includes areas for commonly recognized adverse events as a result of cumulative steroid exposure. It is weighted and measures both worsening and improvement. Scores range from -346 to 439 with cumulative worsening score relating to an increase in GC toxicity burden. - points indicate improvement, + points indicate worsening. The higher the patient's burden of glucocorticoid toxicity, the higher his score.
Interventions
None listed
Sponsors
Hacettepe University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 18 years and over * Individuals who have received glucocorticoid treatment for RA, SLE or vasculitis in the last 2 years or at current admission. * Patients approved by the physician to participate in the study * Patients giving written consent
Exclusion criteria
* Younger than 18 * Patients with communication disabilities * Patients involved in another clinical and/or drug trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in Glucocorticoid Toxicity Index (GTI) scores | Each patient will be followed up for a total of 6 months, at 3 and 6 months. | In this study, it is predicted that a change in GTI scores will be achieved during 3-month follow-up in patients with long-term and newly diagnosed RA, SLE and vasculitis. When the 6-month follow-up of each patient is completed, the study will be terminated. In this study, the side effects of glucocorticoids used by patients will be evaluated using the Glucocorticoid Toxicity Index (GTI) index. This index includes areas for commonly recognized adverse events as a result of cumulative steroid exposure. It is weighted and measures both worsening and improvement. Scores range from -346 to 439 with cumulative worsening score relating to an increase in GC toxicity burden. - points indicate improvement, + points indicate worsening. The higher the patient's burden of glucocorticoid toxicity, the higher his score. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactMelda Bahap, master of science
Backup ContactEmine Duran, md
Outcome results
None listed